PANPHA

Panpha is a clinical-stage biotechnology company based in Shanghai, China, focused on developing innovative small molecule drugs for oncology and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target intracellular signaling pathways that modulate the immune system's response to cancer. Its lead program, PAN-908, is a potent and selective HPK1 inhibitor currently in Phase 1 clinical trials for patients with advanced solid tumors. Panpha's pipeline also includes a STING agonist (PAN-301) and other undisclosed programs aimed at overcoming resistance to current immunotherapies. The company is backed by prominent venture capital firms and aims to deliver transformative treatments for patients with high unmet medical needs.